# Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes

> **NCT06989723** · PHASE4 · RECRUITING · sponsor: **Seoul National University Bundang Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Type 2 Diabetes
- Fatty Liver

## Interventions

- **DRUG:** Pioglitazone 15 MG [Actos]
- **DRUG:** Empagliflozin 10 MG [Jardiance]
- **DRUG:** Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]

## Key facts

- **NCT ID:** NCT06989723
- **Lead sponsor:** Seoul National University Bundang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06989723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06989723, "Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06989723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*